Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors can seem to get enough of Reddit penny stocks news as it continues to be a hot topic among traders. Of course, we’re not one to deny the people what they want, which is why we’re taking a look at the...
3 Penny Stocks Making Big Waves in the Biotech Industry Penny stocks have remained some of the most popular assets over the past year or so. While this began as a way to capitalize on penny stocks benefitting from the pandemic, investors are now finding biotech stocks simply bec...
Gainers: Galera Therapeutics (GRTX) +26%, Ocular Therapeutix (OCUL) +17%, Capricor Therapeutics (CAPR) +15%, AtriCure (ATRC) +12%, Atossa Therapeutics (ATOS) +14%.Losers: Adverum Biotechnologies (ADVM) -60%, Cara Therapeutics (CARA) -44%,...
Galera Therapeutics (GRTX) +41% on updating data from pancreatic cancer trial.Willamette Valley Vineyards (WVVI) +18%.Nokia Corporation (NOK) +17% on Q1 results.VEREIT (VER) +17% as Realty Income to acquire the company.Enlivex Therapeutics (ENLV) +13%.Pluristem Therapeutics (PS...
Atossa has two clinical programs in breast cancer and COVID. After a major surge earlier this year, shares are back in a downtrend. Many hurdles remain to reach approval. Investors are best served swinging shares or waiting for more data. For further details see: Ato...
Atossa Therapeutics (ATOS) announces that an ovarian cancer patient has begun treatment with the company's proprietary oral Endoxifen.The FDA previously issued a "Safe to Proceed" letter under their expanded access pathway, permitting the use of Atossa’s oral Endoxifen in this patient,...
SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that an ovari...
Biotech Penny Stocks For Your Q2 Watch List Biotech penny stocks have been some of the most consistently watched names over the past year. The pandemic definitely helped shed light on this industry. It also saw millions of new traders flock to buy the next big breakout stock working...
Atossa Therapeutics (ATOS): FY GAAP EPS of -$1.97 misses by $0.76.Cash, cash equivalents and restricted cash of $39.7M.Press Release For further details see: Atossa Therapeutics EPS misses by $0.76
SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announced financ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...